iZafe Group Announces the Appointment of Nomination Committee

STOCKHOLM, SE / ACCESSWIRE / November 13, 2023 / iZafe Group (STO:IZAFE-B) iZafe Group AB (publ.) is pleased to announce that the company’s major shareholders have appointed a nomination committee in consultation with the chairman of the board, Björn Rosengren. This step marks a significant milestone in enhancing corporate governance and ensuring that the company’s leadership is aligned with shareholder interests and strategic objectives.

The Nomination Committee comprises the following members, representing a diverse mix of the company’s ownership:

  • Patrik Björn, representing personal holdings through Gästrike Nord Invest AB
  • Stefan Wård, representing personal holdings
  • Marc Tarruell Tibau, representing personal holdings through Timedi S.L.
  • Björn Rosengren, Chairman of the Board, iZafe Group AB

Stefan Wård has been appointed as the Chairman of the Nomination Committee.

The Nomination Committee represents approximately 33% of the total number of outstanding shares and votes.

The primary responsibility of the Nomination Committee is to prepare and present proposals for the Annual General Meeting, on May 30 2024, regarding the election of the meeting’s chairman, the Board of Directors, the Chairman of the Board, and auditors. The committee will also propose fees for board members and remuneration for auditors.

Shareholders in iZafe Group are encouraged to submit proposals to the Chairman of the Nomination Committee. Submissions can be made via email at valberedning@izafegroup.com or by postal mail to: iZafe Group, Attn: Nomination Committee, David Bagares Gata 3, 111 38 Stockholm, Sweden.

This initiative underscores iZafe Group’s commitment to robust corporate governance practices that support the company’s long-term strategy and value creation for shareholders.

Contacts

Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
David Bagares gata 3
111 38 Stockholm

E-mail: ir@izafegroup.com
www.izafegroup.com
eucaps.com/izafe-group

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company’s solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company’s Certified Adviser. Further information is available at www.izafegroup.com

Image Attachments

Valberedning 2024

Attachments

iZafe Group announces the appointment of nomination committee

SOURCE: iZafe Group

View source version on accesswire.com:
https://www.accesswire.com/802556/izafe-group-announces-the-appointment-of-nomination-committee

Staff

Recent Posts

American College of Osteopathic Family Physicians Announces 2024-2025 Board of Governors

CHICAGO, IL / ACCESSWIRE / April 3, 2024 / The American College of Osteopathic Family…

2 hours ago

ACOFP Foundation Announces New Campaign, Family Medicine Forward

Campaign underscores the urgency and need to support early career osteopathic family physicians.CHICAGO, IL /…

5 hours ago

Reveal Lasers Reports First Quarter With Record-Breaking 300% Growth

LAS VEGAS, NV / ACCESSWIRE / April 3, 2024 / Reveal Lasers, a burgeoning force…

8 hours ago

Weave Enhances Integration with DrChrono by EverHealth

Deeper integration unlocks powerful Weave features to improve patient experiencesLEHI, Utah--(BUSINESS WIRE)--Weave (NYSE: WEAV), a…

11 hours ago

Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature

CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that…

11 hours ago

LPW Training Services Awarded the Association for Talent Development’s Excellence in Practice for 2024

SOMERVILLE, NJ / ACCESSWIRE / April 3, 2024 / LPW Training Services, a global industry…

11 hours ago